Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18908266 | 1.00 | KCNH2 (0.32) | KCNH2TMEM97SIGMAR1FAAHSMN1; SMN2 | |
| SCHEMBL18908287 | 0.85 | SMN1; SMN2 (0.34) | FAAHSMN1; SMN2NPSR1LMNAMAPT | |
| SCHEMBL18908273 | 0.81 | ALDH1A1 (0.39) | SMN1; SMN2LMNAKMT2AHTR2AHTR2C | |
| SCHEMBL18908296 | 0.81 | ALDH1A1 (0.39) | SMN1; SMN2LMNAKMT2AHTR2AHTR2C | |
| SCHEMBL19361587 | 0.81 | HTR2A (0.36) | KCNH2TMEM97SIGMAR1SMN1; SMN2LMNA | |
| SCHEMBL19361586 | 0.78 | KDM4E (0.38) | MAPTHTR2AHTR2C | |
| SCHEMBL18972020 | 0.77 | SLC6A2 (0.41) | NPSR1MEN1KMT2A | |
| SCHEMBL18821185 | 0.77 | KCNH2 (0.38) | KCNH2TMEM97SIGMAR1SMN1; SMN2HTR2A | |
| SCHEMBL19361582 | 0.76 | USP2 (0.39) | SMN1; SMN2LMNAMEN1KMT2ACYP1A2 | |
| SCHEMBL18820640 | 0.76 | USP2 (0.40) | KCNH2TMEM97SIGMAR1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| WO-2017091617-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT1 | KCNH2 4441/4885TMEM97 4016/4885SIGMAR1 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.